Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RNA, U6 small nuclear 129, pseudogene (RNU6-129P) is classified as a pseudogene related to the family of U6 small nuclear RNAs, which are core non-coding RNA components of the spliceosome complex responsible for pre-mRNA splicing in eukaryotes. As a pseudogene, RNU6-129P is considered non-functional in terms of encoding an active snRNA or protein product. While active U6 snRNA genes play an essential role in catalyzing splicing reactions, pseudogenes like RNU6-129P typically arise from duplication or retrotransposition events and generally lack the regulatory elements or sequence integrity to produce functional transcripts[1][5][4]. Some pseudogenes in the genome can generate regulatory RNAs with possible roles in gene regulation (e.g., as antisense RNAs or competing endogenous RNAs), but there is no specific evidence that RNU6-129P is functional or implicated in disease, nor is it a therapeutic target[4][5][1]. This locus is important primarily as a genomic marker and not as a direct functional molecule.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA, U6 small nuclear 129, pseudogene (RNU6-129P).